- Isatuximab for the treatment of relapsed/refractory multiple myeloma2020 | First Faculty of Medicine
- Relapsing / refractory pediatric ALL: allogeneic SCT or CAR-T cells?2021 | Second Faculty of Medicine
- Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma2019 | First Faculty of Medicine
- Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma2021 | Faculty of Medicine in Hradec Králové
- Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy2018 | First Faculty of Medicine
- Treatment of patients with relapsed/refractory Hodgkin lymphoma2011 | First Faculty of Medicine
- The Proteasome Inhibitor Bortezomib (Velcade) in he Treatment of Relapsed/Refractory Multiple Myeloma. The First Experience in the Czech Republic2005 | First Faculty of Medicine
- Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA2022 | First Faculty of Medicine
- Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis2021 | Faculty of Medicine in Hradec Králové
- Treatment of patients with relapsed/refractory Hodgkin lymphoma2011 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma2018 | Third Faculty of Medicine
- Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia2012 | Faculty of Medicine in Hradec Králové
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia2019 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Report of University Hospital Hradec Králové to the clinical trial protocol No: APL-C-001-09Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: C-5013-NHL-007Publication without faculty affiliation
- Benefit of continuous lenalidomide therapy in patients with relapsed / refractory multiple myeloma2013 | Faculty of Medicine in Hradec Králové
- Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma The First Experience in the Czech Republic2005 | First Faculty of Medicine
- MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial2020 | Faculty of Medicine in Hradec Králové
- Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia2020 | Publication without faculty affiliation
- Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma2020 | First Faculty of Medicine
- A Phase I study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)2021 | Second Faculty of Medicine
- Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results2022 | Faculty of Medicine in Hradec Králové
- Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma2016 | Faculty of Medicine in Hradec Králové
- Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma2020 | First Faculty of Medicine, Second Faculty of Medicine
- Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT2021 | First Faculty of Medicine
- CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics2022 | Second Faculty of Medicine
- Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study2018 | Second Faculty of Medicine